Analysed ROCKET PHARMACEUTICALS IN-27 (RCKTW:NASDAQ) News Sources
Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says
08-05-2026
yahoo.com
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
12-06-2026
yahoo.com
Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?
25-06-2026
yahoo.com
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
03-08-2026
yahoo.com
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
10-08-2026
yahoo.com
Rocket Pharmaceuticals' Danon, PKP2-ACM Updates Seen as Key H2 Catalysts, Wedbush Says
11-08-2026
yahoo.com
What is the current price of ROCKET PHARMACEUTICALS IN-27 (RCKTW:NASDAQ)?
The current price of ROCKET PHARMACEUTICALS IN-27 (RCKTW:NASDAQ) is $0.0004.
ROCKET PHARMACEUTICALS IN-27 (RCKTW:NASDAQ) absolute price change since previous trading day?
The absolute price change of ROCKET PHARMACEUTICALS IN-27 (RCKTW:NASDAQ) since the previous trading day is $-0.0003.
ROCKET PHARMACEUTICALS IN-27 (RCKTW:NASDAQ) percentage price change since previous trading day?
The percentage price change of ROCKET PHARMACEUTICALS IN-27 (RCKTW:NASDAQ) since the previous trading day is -42.8571%.
What is the most recent average sentiment score for ROCKET PHARMACEUTICALS IN-27 (RCKTW:NASDAQ)?
The most recent average sentiment score for ROCKET PHARMACEUTICALS IN-27 (RCKTW:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for ROCKET PHARMACEUTICALS IN-27 (RCKTW:NASDAQ)?
The most recent sentiment for ROCKET PHARMACEUTICALS IN-27 (RCKTW:NASDAQ) is .
SEC-8K** Filing Available For ROCKET PHARMACEUTICALS IN-27 (RCKTW:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.